Rami S. Komrokji

Featured in: Favicon

nature.com Favicon

wiley.com (+1) Favicon

thelancet.com Favicon

healio.com Favicon

ashpublications.org Favicon

bloodjournal.org Favicon

futuremedicine.com Favicon

onclive.com Favicon

targetedonc.com Favicon

oncnursingnews.com + 1 more

Articles

Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study - Leukemia

Nov 12, 2024 | nature.com | Douglas Tremblay |Clifford M. Csizmar |Courtney DiNardo |Danielle Hammond |Tapan M Kadia |Farhad Ravandi | +10 more

Chronic myelomonocytic leukemia (CMML) is a rare hematologic malignancy with overlapping features of myelodysplastic neoplasm (MDS) and myeloproliferative neoplasms characterized by peripheral blood monocytosis [1]. There is a predisposition for transformation to acute myeloid leukemia (AML), termed CMML with blast transformation (CMML-BT) [2, 3].
Dr Komrokji on Ongoing Investigations With Luspatercept in MDS

Nov 3, 2023 | onclive.com | Rami S. Komrokji

November 3, 2023Supplements And Featured Publications2023 SOHO Meeting ReporterRami Komrokji, MD, discusses the benefit of agents such as luspatercept-aamt in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with erythropoiesis-stimulating agents.
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts | Leukemia

Sep 26, 2023 | nature.com | Uwe Platzbecker |Valeria Santini |Rami S. Komrokji |Guillermo Garcia-Manero

To the Editor:Myelodysplastic syndromes (MDS) are disorders of hematopoietic stem cells characterized by ineffective hematopoiesis, commonly leading to anemia [1]. The main goals in the treatment of lower-risk MDS (LR-MDS) are to manage anemia, improve or maintain quality of life (QoL), and delay disease progression to higher-risk MDS (HR-MDS) and acute myeloid leukemia (AML) [1, 2]. Chronic anemia in LR-MDS is associated with increased mortality and morbidity rates [3, 4].
Komrokji on the Classification of MDS

Jun 16, 2023 | targetedonc.com | Rami S. Komrokji

Rami Komrokji, MD, vice chair of the Department of Malignant Hematology and head of the Leukemia and MDS Section at Moffitt Cancer Center in Tampa, Florida, discusses the different systems of classifying myelodysplastic syndrome (MDS) and how combining the current classification systems into 1 may provide more benefit for clinicians and their patients. Many subtypes of MDS exist and are determined using results of blood and bone marrow tests.